Free NuvaRing lawsuit evaluations for those who have sustained serious injuries, such as blood clots and pulmonary embolisms, while using NuvaRing. Call 1-800-403-6191 or visit www.FightForVictims.com
Free NuvaRing lawsuit evaluations for those who have sustained serious injuries, such as blood clots and pulmonary embolisms, while using NuvaRing. To discuss a NuvaRing lawsuit claim, contact us at 1-800-403-6191 or visit www.FightForVictims.com
New York, NY (PRWEB) August 19, 2013
A NuvaRing lawsuit has recently been filed against Organon and others by the defective drug lawyers at Alonso Krangle. This case (Case No. 2:13-cv-03061-SDW-MCA), which was filed on May 15, 2013 against both Organon USA, Inc. and Merck & Co., Inc., has been filed on behalf of a Virginia woman in the U.S. District Court of New Jersey.
NuvaRing Lawsuit Case Number (Case No. 2:13-cv-03061-SDW-MCA) U.S. District Court of New Jersey
According to NuvaRing lawsuit documents for this case, the plaintiff began using NuvaRing in February 2011. Within four months of using NuvaRing, the plaintiff began to develop chest pain and shortness of breath. Seeking medical attention for these symptoms, the plaintiff underwent a CT scan, which revealed that she had developed bilateral pulmonary emboli (a potentially life-threatening condition in which blood clots lodge in and block the proper oxygen flow through the lungs). Upon receiving this diagnosis, the plaintiff was immediately hospitalized, at which time she was placed on anticoagulation therapy, including Lovenox and Coumadin. Since being released from the hospital, the plaintiff has had to continue her anticoagulation therapy and has had to undergo regular follow-up care to monitor her health.
This NuvaRing lawsuit (Case No. 2:13-cv-03061-SDW-MCA) claims that the plaintiff’s use of NuvaRing was directly responsible for her development of pulmonary embolism. Additionally, this NuvaRing lawsuit case also alleges that Organon and Merck knew about the serious risks of blood clot-realted complications associated with NuvaRing use but failed to warn the public about these risks. Instead, according to the NuvaRing lawsuit complaint, the defendants marketed NuvaRing as safe and effective, putting many women at risk of possibly developing severe NuvaRing side effects.
( fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm117851.htm )
Alonso Krangle’s experienced NuvaRing lawsuit attorneys are dedicated to standing up for victims’ rights and holding even the largest corporations accountable for their potentially dangerous medications. We offer free NuvaRing lawsuit evaluations to those who have sustained serious injuries, such as blood clots and pulmonary embolisms, that could be linked to the use of NuvaRing. To discuss a potential NuvaRing lawsuit claim with one of the compassionate NuvaRing lawyers at Alonso Krangle LLP, please contact us at 1-800-403-6191 or visit our website, http://www.FightForVictims.com.
Serious NuvaRing Complications Reported by Researchers and FDA
Various researchers have reported finding a link between NuvaRing use and serious blood clot disorders like deep vein thrombosis and pulmonary embolism within recent years. Specifically, a 2012 study published in the New England Journal of Medicine reported that vaginal rings like NuvaRing could nearly triple women’s risk of developing blood clots when compared to the risk associated with older birth control pills. [ http://www.nejm.org/doi/full/10.1056/NEJMoa1111840 Similarly, another study published in the May 2012 British Medical Journal reported that women’s risk of developing blood clots increased by more than 6 times when using vaginal rings like NuvaRing, as opposed to birth control pills.
( http://www.bmj.com/content/344/bmj.e2990#alternate 10 May 2012 ]
( http://www.nejm.org/doi/full/10.1056/NEJMoa1111840 June 14, 2012 )
Such research findings have been backed up by data collected by the FDA’s Adverse Events Reporting System (AERS). Specifically, the AERS has received more than 5,350 reports of serious adverse events related to NuvaRing use since the drug was first introduced in 1997 (though FDA approval was not granted until 2001). Among the most commonly reported adverse effects associated with NuvaRing use were more than 1,170 incidents of pulmonary embolism and more than 1,150 incidents of thrombosis and deep vein thrombosis. According to the FDA AERS, more than 30 percent of women who reported NuvaRing complications had to be hospitalized due to the severity of their injuries, and approximately 3 percent of NuvaRing complications resulted in death.
FDA's drug Adverse Event Reporting System AERS
( adverseevents.com/drugdetail.php?AEDrugID=4584&BrandName=NUVARING )
( drugcite.com/?q=NuvaRing )
( fdable.com/basic_query/aers/c098aabb9852a99f2e7eaa6fd4ea9c10 )
( rxisk.org/Research/DrugInformation.aspx?DrugID=4773&ProductDrugID=42274&ProductName=Nuvaring#7_0_0_0_0__--__ )
About Alonso Krangle LLP And Filing A NuvaRing Lawsuit
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on handling significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey.
For more information about Alonso Krangle or to join the fight and be a part of our team, please contact us at 1-800-403-6191 or visit our website, FightForVictims.com.